

WHO Expert Committee on Drug Dependence

Twentieth Report

Technical Report Series

551



World Health Organization, Geneva 1974

This report contains the collective views of an international group of experts and does not necessarily represent the decisions or the stated policy of the World Health Organization.

WORLD HEALTH ORGANIZATION

TECHNICAL REPORT SERIES

No. 551

WHO EXPERT COMMITTEE ON DRUG DEPENDENCE

Twentieth Report

WORLD HEALTH ORGANIZATION

GENEVA

1974

WORLD HEALTH ORGANIZATION
TECHNICAL REPORT SERIES

No. 351

WHO EXPERT COMMITTEE
ON DRUG DEPENDENCE

Tenth Report

ISBN 92 4 120551 2

© World Health Organization 1974

Publications of the World Health Organization enjoy copyright protection in accordance with the provisions of Protocol 2 of the Universal Copyright Convention. For rights of reproduction or translation of WHO publications in part or *in toto*, application should be made to the Office of Publications and Translation, World Health Organization, Geneva, Switzerland. The World Health Organization welcomes such applications.

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the Director-General of the World Health Organization concerning the legal status of any country or territory or of its authorities, or concerning the delimitation of its frontiers.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

PRINTED IN SWITZERLAND

The World Health Organization (WHO) is one of the specialized agencies in relationship with the United Nations. Through this organization, which came into being in 1948, the public health and medical professions of more than 140 countries exchange their knowledge and experience and collaborate in an effort to achieve the highest possible level of health throughout the world. WHO is concerned primarily with problems that individual countries or territories cannot solve with their own resources—for example, the eradication or control of malaria, schistosomiasis, smallpox, and other communicable diseases, as well as some cardiovascular diseases and cancer. Progress towards better health throughout the world also demands international cooperation in many other activities : for example, setting up international standards for biological substances, for pesticides and for pesticide spraying equipment ; compiling an international pharmacopoeia ; drawing up and administering the International Health Regulations ; revising the international lists of diseases and causes of death ; assembling and disseminating epidemiological information ; recommending nonproprietary names for drugs ; and promoting the exchange of scientific knowledge. In many parts of the world there is need for improvement in maternal and child health, nutrition, nursing, mental health, dental health, social and occupational health, environmental health, public health administration, professional education and training, and health education of the public. Thus a large share of the Organization's resources is devoted to giving assistance and advice in these fields and to making available—often through publications—the latest information on these subjects. Since 1958 an extensive international programme of collaborative research and research coordination has added substantially to knowledge in many fields of medicine and public health. This programme is constantly developing and its many facets are reflected in WHO publications.

* * *

Expert committees and other international groups of experts are convened to give advice on technical and scientific matters. Members of such expert groups serve without remuneration in their personal capacity and not as representatives of governments or other bodies. The selection of members of international groups is based primarily on their ability and technical experience, with due regard to adequate geographical distribution.

The WHO *Technical Report Series* is the vehicle of publication of collective reports of such groups. Although these reports do not necessarily represent the views of the Organization, they are taken into consideration when developing programmes.

Annual Subscription : £10.50, \$24.50, or Sw. fr. 70.—.

Public health workers and institutions that wish to be kept informed of new reports of expert groups in the *Technical Report Series* can do so by regular reference to the summaries of these reports given in the *WHO Chronicle*, which is published monthly in Chinese, English, French, Russian, and Spanish.

Annual Subscription : £2,70, \$6.30, or Sw. fr. 18.—.

CONTENTS

	Page
Introduction	7
 PART I. WORK OF INTERNATIONAL BODIES CONCERNED WITH DRUG DEPENDENCE	
1. World Health Organization	8
2. United Nations	9
3. International Narcotics Control Board	11
4. United Nations Educational, Scientific and Cultural Organization	12
5. International Council on Alcohol and Addictions	12
 PART II. PREVENTION OF PROBLEMS ASSOCIATED WITH DRUG USE	
1. General	12
1.1 Use of terms	14
1.2 Focus of report	17
1.3 Bases of programme formulation	19
2. Factors associated with the nonmedical use of drugs	20
2.1 General factors	20
2.2 Initial and experimental use	22
2.3 Casual use	24
2.4 Dependent use	25
2.5 Stopping use	27
3. Approaches to prevention	29
3.1 Some planning considerations	29
3.2 Goals of problem prevention	32
3.3 Measures directed primarily toward limiting the availability of drugs	35
3.4 Measures directed primarily at individuals and small groups	37
3.4.1 Identification of persons at high risk of experiencing drug- related problems	37
3.4.2 Peer group influences	43
3.4.3 Role of drug information and education programmes	44
3.5 Measures directed primarily at the environment	49
3.5.1 Monitoring the environment	51
3.5.2 Improving the effectiveness of social controls	52
3.5.3 Meaningful alternatives	57
3.5.4 Alleviating general environmental stress	59
3.6 Special considerations relating to alcoholic beverages	60
3.6.1 Problems associated with "excessive" drinking	61
3.6.2 The question of specific beverage consumption	68

3.6.3	Advertising	69
3.6.4	Level of acceptance	69
3.6.5	Price in relation to purchasing power	70
3.6.6	Recommendations	71
3.7	Concerted action	72
3.7.1	Functions to be carried out	73
3.7.2	Means of fostering concerted action	75
3.8	Role of research	77
3.8.1	Evaluative studies	78
3.8.2	Improving preventive programmes	80
4.	Conclusions and recommendations	82
4.1	General	82
4.2	Availability of drugs	83
4.3	Individuals and small groups	84
4.4	Environment	86
4.5	Special considerations related to alcoholic beverages	87
4.6	Research	88

PART III. INTERNATIONAL CONTROL OF INDIVIDUAL DRUGS

1.	Difenoxin	88
2.	Preparations containing difenoxin	89

This report contains the collective views of an international group of experts and does not necessarily represent the decisions or the stated policy of the World Health Organization.

WORLD HEALTH ORGANIZATION

TECHNICAL REPORT SERIES

No. 551

WHO EXPERT COMMITTEE ON DRUG DEPENDENCE

Twentieth Report

WORLD HEALTH ORGANIZATION

GENEVA

1974

ISBN 92 4 120551 2

© World Health Organization 1974

Publications of the World Health Organization enjoy copyright protection in accordance with the provisions of Protocol 2 of the Universal Copyright Convention. For rights of reproduction or translation of WHO publications in part or *in toto*, application should be made to the Office of Publications and Translation, World Health Organization, Geneva, Switzerland. The World Health Organization welcomes such applications.

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the Director-General of the World Health Organization concerning the legal status of any country or territory or of its authorities, or concerning the delimitation of its frontiers.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

PRINTED IN SWITZERLAND

CONTENTS

	Page
Introduction	7
 PART I. WORK OF INTERNATIONAL BODIES CONCERNED WITH DRUG DEPENDENCE	
1. World Health Organization	8
2. United Nations	9
3. International Narcotics Control Board	11
4. United Nations Educational, Scientific and Cultural Organization	12
5. International Council on Alcohol and Addictions	12
 PART II. PREVENTION OF PROBLEMS ASSOCIATED WITH DRUG USE	
1. General	12
1.1 Use of terms	14
1.2 Focus of report	17
1.3 Bases of programme formulation	19
2. Factors associated with the nonmedical use of drugs	20
2.1 General factors	20
2.2 Initial and experimental use	22
2.3 Casual use	24
2.4 Dependent use	25
2.5 Stopping use	27
3. Approaches to prevention	29
3.1 Some planning considerations	29
3.2 Goals of problem prevention	32
3.3 Measures directed primarily toward limiting the availability of drugs	35
3.4 Measures directed primarily at individuals and small groups	37
3.4.1 Identification of persons at high risk of experiencing drug- related problems	37
3.4.2 Peer group influences	43
3.4.3 Role of drug information and education programmes	44
3.5 Measures directed primarily at the environment	49
3.5.1 Monitoring the environment	51
3.5.2 Improving the effectiveness of social controls	52
3.5.3 Meaningful alternatives	57
3.5.4 Alleviating general environmental stress	59
3.6 Special considerations relating to alcoholic beverages	60
3.6.1 Problems associated with "excessive" drinking	61
3.6.2 The question of specific beverage consumption	68

3.6.3	Advertising	69
3.6.4	Level of acceptance	69
3.6.5	Price in relation to purchasing power	70
3.6.6	Recommendations	71
3.7	Concerted action	72
3.7.1	Functions to be carried out	73
3.7.2	Means of fostering concerted action	75
3.8	Role of research	77
3.8.1	Evaluative studies	78
3.8.2	Improving preventive programmes	80
4.	Conclusions and recommendations	82
4.1	General	82
4.2	Availability of drugs	83
4.3	Individuals and small groups	84
4.4	Environment	86
4.5	Special considerations related to alcoholic beverages	87
4.6	Research	88

PART III. INTERNATIONAL CONTROL OF INDIVIDUAL DRUGS

1.	Difenoxin	88
2.	Preparations containing difenoxin	89

WHO EXPERT COMMITTEE ON DRUG DEPENDENCE

Geneva, 8-13 October 1973

Members : *

- Mr H. D. Archibald, Executive Director, Addiction Research Foundation, Toronto, Ont., Canada
- Dr E. A. Babajan, Head, Department for the Introduction of New Drugs and Medical Technology, Ministry of Health of the USSR, Moscow, USSR
- Dr B. S. Brown, Director, National Institute of Mental Health, Department of Health, Education, and Welfare, Rockville, Md., USA (*Chairman*)
- Dr K. Evang, former Director General of Health Services, Oslo, Norway (*Vice-Chairman*)
- Dr J. H. Jaffe, Professor of Psychiatry, Columbia University College of Physicians and Surgeons, New York, N.Y., USA
- Dr A. Stoller, Chairman, Mental Health Authority, Melbourne, Vic., Australia (*Rapporteur*)

Representatives of other organizations :

United Nations

- Dr O. J. Braenden, Chief, Scientific and Technical Section, Division of Narcotic Drugs, United Nations, Geneva, Switzerland
- Dr J. L. Gomez del Prado, Drug Demand and Information Unit, Division of Narcotic Drugs, United Nations, Geneva, Switzerland
- Mr E. Hytten, Chief, European Social Development Programme Unit, Division of Social Affairs, United Nations, Geneva, Switzerland
- Dr S. G. R. Mårtens, Director, Division of Narcotic Drugs, United Nations, Geneva, Switzerland
- Mr J. J. Moore, Research Expert, United Nations Social Defence Research Institute, Rome, Italy

United Nations Educational, Scientific and Cultural Organization

- Miss N. Friderich, Division of Curricula and Structures, Unesco, Paris, France

International Narcotics Control Board

- Mr L. Manueco-Jenkins, Chief, Treaty, Research and Information, INCB, Geneva, Switzerland

International Council on Alcohol and Addictions

- Dr H. Halbach, Honorary Professor of Pharmacology, University of Munich, Federal Republic of Germany
- Mrs E. J. Tongue, Assistant Director, ICAA, Lausanne, Switzerland
- Dr P. H. Connell, Director, Drug Dependence Clinical Research and Treatment Unit, the Bethlem Royal Hospital and the Maudsley Hospital, London, England

* *Unable to attend* : Dr J. Griffith Edwards, Honorary Director, Addiction Research Unit, Institute of Psychiatry, London, England ; Dr Komol Pengsritong, Under-Secretary of State for Public Health, Ministry of Public Health, Bangkok, Thailand ; and Dr M. I. Soueif, Professor of Psychology, Faculty of Arts, University of Cairo, Egypt.

Secretariat :

Dr D. C. Cameron, Senior Medical Officer, Office of Mental Health, WHO, Geneva, Switzerland (*Secretary*)

Dr T. L. Chruściel, Senior Medical Officer, Office of Mental Health, WHO, Geneva, Switzerland

Dr A. N. Little, Head, Reference Division, Community Relations Commission, London, England (*Consultant*)

Dr W. H. McGlothlin, Professor in Residence, Department of Psychology, University of California, Los Angeles, Calif., USA (*Consultant*)

Dr H. H. Nowlis, Director, Office of Drug Education/Health and Nutrition Programs, Department of Health, Education, and Welfare, Washington, D.C., USA (*Consultant*)

Dr E. Stålberg, Assistant Professor of Neurophysiology, Department of Clinical Neurophysiology, Academic Hospital, Uppsala, Sweden (*Consultant*)

WHO EXPERT COMMITTEE ON DRUG DEPENDENCE

Twentieth Report

INTRODUCTION

The WHO Expert Committee on Drug Dependence met in Geneva from 8 to 13 October 1973.

The meeting was opened on behalf of the Director-General by Dr T. Lambo, Assistant Director-General, who welcomed the participants and the representatives of the United Nations, the United Nations Educational, Scientific and Cultural Organization, the International Narcotics Control Board, and the International Council on Alcohol and Addictions. Dr Lambo noted that WHO Expert Committees, Scientific Groups, and Study Groups over more than two decades had given attention to (a) the identification of dependence-producing drugs that can produce individual, public health, and social problems;¹ (b) the similarities and differences between dependence on socially unacceptable dependence-producing drugs and dependence on those whose use was acceptable or tolerated;² (c) the provision of services for the prevention and treatment of dependence on alcohol and other drugs;³ (d) principles for the management of drug dependence problems;⁴ (e) the use of cannabis;⁵ (f) youth and drugs;⁶ and (g) the epidemiological study of drug dependence.⁷ Only a few of these expert groups, beyond making recommendations relative to the imposition of controls on the availability of particular drugs, had taken up the question

¹ *Off. Rec. Wld Hlth Org.*, 1949, No. 19, pp. 29–34; *Wld Hlth Org. techn. Rep. Ser.*, 1950, No. 21; 1952, No. 57; 1954, No. 76; 1955, No. 95; 1956, No. 102; 1957, No. 116; 1958, No. 142; 1960, No. 160; 1960, No. 188; 1961, No. 211; 1962, No. 229; 1964, No. 273; 1964, No. 287; 1965, No. 312; 1966, No. 343; 1969, No. 407; 1970, No. 437; 1971, No. 478; 1972, No. 495.

² *Wld Hlth Org. techn. Rep. Ser.*, 1949, No. 9; 1951, No. 42; 1952, No. 48; 1954, No. 84; 1955, No. 94; 1967, No. 363; 1973, No. 516.

³ *Wld Hlth Org. techn. Rep. Ser.*, 1950, No. 42; 1952, No. 48; 1957, No. 131; 1967, No. 363.

⁴ *Wld Hlth Org. techn. Rep. Ser.*, 1970, No. 460; 1973, No. 516.

⁵ *Wld Hlth Org. techn. Rep. Ser.*, 1971, No. 478.

⁶ *Wld Hlth Org. techn. Rep. Ser.*, 1973, No. 516.

⁷ *Wld Hlth Org. techn. Rep. Ser.*, 1973, No. 526.

of other approaches to prevention.¹ Many governmental and other organizations have initiated a wide variety of activities designed to reduce the present and future problems associated with the nonmedical use of various dependence-producing drugs, and other organizations plan to do so. Current preventive approaches include efforts to (a) prohibit completely the nonmedical use of certain drugs, (b) discourage but not prohibit such use of other drugs, (c) inform community leaders and potential and existing users about the possible consequences of drug use, (d) provide ready access to attractive activities not associated with drug use, and (e) carry out early case-finding activities designed to help limit the spread of drug use. Objective evaluation of the policies, approaches, and methods used is difficult, but insufficient efforts have been made to determine not only their effectiveness but their financial and other costs. Some approaches, when inappropriately applied, could well exacerbate drug-related problems instead of reducing them. It was therefore fitting that the Committee be invited to assess current and possible future approaches to the prevention of problems associated with the nonmedical use of dependence-producing drugs and to consider means of increasing the effectiveness of activities intended to help achieve prevention.

PART I

WORK OF INTERNATIONAL BODIES CONCERNED WITH DRUG DEPENDENCE

The widespread interest in and concern about the individual, public health, and social problems associated with the use of certain dependence-producing drugs outside of acceptable medical practice continue to be reflected by the activities of various international organizations. The Committee was pleased to note and comment on some of these endeavours.

1. WORLD HEALTH ORGANIZATION

The Committee, having been informed that the Twenty-sixth World Health Assembly had (a) stressed anew the need for the World Health Organization "to encourage and assist the development of improved preventive treatment and rehabilitation and training programmes and the

¹ *Wld Hlth Org. techn. Rep. Ser.*, 1967, No. 363, p. 35 (section 3); 1970, No. 460, p. 30 (section 3.4); WHO Regional Office for Europe (1971) *Measures for the prevention and control of drug abuse and dependence*, Copenhagen (EURO 5412 IV, report of a Working Group); WHO Regional Office for Europe (1972) *Health education programmes concerning drug abuse in young people*, Copenhagen (EURO 5418 IV, report of a Working Group).

pursuit of needed knowledge in the field of drug dependence",¹ (b) emphasized the importance it attached "to developing means for the international collection and exchange of data on the prevalence and incidence of drug dependence, and on the complex psychological, sociocultural, internal and external factors associated therewith", and (c) requested that efforts be intensified to implement the expanded programme in the field of drug dependence approved by previous World Health Assemblies,² learned of the activities undertaken by the Organization to these ends. It took particular note of the work of two WHO expert groups;³ the activities of the WHO Regional Office for the Americas in helping to establish a centre in Central America for the study of dependence on alcohol, in providing training courses, and in undertaking planning for epidemiological studies in that Region; the assistance given to countries by the WHO Regional Offices for the Eastern Mediterranean, South-East Asia, the Western Pacific, and Europe; and the conference conducted by the latter Regional Office on evaluation of treatment methods.⁴ Note was also taken of the continuing work on three WHO projects⁵ begun in the previous year with the assistance of the United Nations Fund for Drug Abuse Control (UNFDAC), the initiation of an UNFDAC-assisted study in Iran on the effectiveness of various methods utilized in treating narcotic-dependent persons, and progress made on the UNFDAC-supported Treatment and Rehabilitation Project in Thailand.

2. UNITED NATIONS

The United Nations Fund for Drug Abuse Control (UNFDAC)⁶ now has resources of approximately US \$10 million and has made funds available to a number of international bodies for a wide variety of programmes in the field of drug dependence. Noting that in the past it had not been pos-

¹ *Off. Rec. Wld Hlth Org.*, 1973, No. 209, p. 27 (Resolution WHA26.52).

² World Health Organization (1973) *Handbook of resolutions and decisions of the World Health Assembly and the Executive Board, Vol. I, 1948-1972*, p. 123 (Resolution WHA24.57); p. 124 (Resolution WHA25.62).

³ Working Group on Guidelines for Collaborative Reporting on the Non-medical Use of Dependence-producing Drugs, Geneva, 13-18 August 1973; Working Group on WHO Drug Dependence Research and Training Centres, Geneva, 20-24 August 1973.

⁴ WHO Regional Office for Europe (1974) *Comparison and evaluation of methods of treatment and rehabilitation for drug dependence and abuse*, Copenhagen (EURO 5423 IV, report on a Conference).

⁵ Study on the chronic effects of long-term cannabis use; study on the therapeutic effectiveness of maintenance in the management of narcotic-dependent persons; preparation of a brochure for medical and related professions on the nonmedical use of dependence-producing drugs.

⁶ *Wld Hlth Org. techn. Rep. Ser.*, 1973, No. 526, p. 7 (section 2).

sible to achieve effective suppression of the supply of dependence-producing drugs where a very substantial demand existed for their use (e.g., the attempted prohibition of the use of alcohol in Norway and the USA and of opium and opiates in Iran and Thailand), the Committee was pleased to learn that UNFDAC and the international bodies concerned were endeavouring to develop a truly balanced approach to the problems of supply and demand. Only through such an approach in a given geographic region did there appear to be any realistic hope of reducing the extent and seriousness of present and future problems associated with the nonmedical use of drugs.

It was noted that the programme of the United Nations Division of Narcotic Drugs had been substantially expanded in the last two years as a result of, among other things, support made available by UNFDAC. Particular efforts were being made to assist in the development of programmes in given geographic areas that would simultaneously seek to decrease the illicit production of narcotics, suppress illicit traffic, and reduce the demand for such drugs through treatment and rehabilitation and educational activities. The Division was now implementing or had completed some 30 projects supported by UNFDAC, including such activities as country projects of the type just noted, training seminars for enforcement officials, and biochemical research.

In addition to the long-standing (and recently expanded) activities of the United Nations Division of Narcotic Drugs, the Committee noted that within the last two years the United Nations Social Defence Research Institute had undertaken to foster epidemiological and evaluative research by study teams in a number of countries, and the United Nations Division of Social Affairs had become concerned with community reactions to the non-medical use of drugs¹ and the broad, social implications of the problems associated with such use.

Acting on a resolution adopted by the United Nations Commission on Narcotic Drugs,² the Economic and Social Council had invited WHO to assist the Commission "by preparing timely reports on the epidemiological patterns of drug abuse",³ an invitation that was accepted, subject to the availability of funds, by the Twenty-sixth World Health Assembly.⁴

¹ United Nations Division of Social Affairs (1972) *Expert Group on drugs in modern society: community reactions to drug use by young people*, Geneva (Document SOA/ESDP/1972/7).

² United Nations, Commission on Narcotic Drugs (1973) Document E/5248, p. 143, Resolution 10 (XXV) (*Economic and Social Council: Official Records*).

³ United Nations, Economic and Social Council (1973) *Official Records, Fifty-fourth Session, Resolutions, Supplement No. 1*, Document E/5367, p. 21 (Resolution 1781 (LIV)).

⁴ *Off. Rec. Wld Hlth Org.*, 1973, No. 209, p. 27 (Resolution WHA26.52).

The Committee was informed about a number of other resolutions adopted by international bodies that, among other things, (a) invited appropriate international agencies to cooperate fully in the United Nations programme of action in this field and “to pay special attention, in the formulation of their own programmes relating to the socio-economic consequences of drug abuse, to appropriate means of combating this abuse”;¹ (b) considering that “action by governments and international organs and organizations must be taken simultaneously on all fronts: prevention of abuse, repression of illicit traffic, control of production, manufacture, distribution and consumption, development of training and education, scientific research, treatment and rehabilitation” and that better coordination of all efforts was required, requested “the Secretary-General to study the problem and attempt to solve it”;² (c) authorized the establishment of a “sub-commission on illicit drug traffic and related matters in the Near and Middle East” and work on the same problems by an *Ad Hoc* Committee for the Far East Region;³ and (d) recommended “Governments that are not yet parties to the Convention on Psychotropic Substances⁴ to ratify or accede to this Convention”.⁵ In connexion with point (b) above, the Committee was pleased to learn of a recent meeting of various United Nations agencies convened by the Administrative Committee on Co-ordination at which it was recommended that an inter-agency advisory committee on drug abuse control should be established to address itself to the coordination of programmes in this field. In connexion with item (d) above, the Committee was disappointed to learn that only 13 countries had so far adhered to the Convention on Psychotropic Substances and expressed the hope that the Convention would soon come into force.⁶

3. INTERNATIONAL NARCOTICS CONTROL BOARD

The International Narcotics Control Board had continued to exercise its responsibilities under existing international treaties limiting the use of

¹ United Nations General Assembly. Resolution 3014 (XXVII). In: *Official Records of the General Assembly, Twenty-seventh Session, Supplement No. 30 (A/8730)*, p. 68.

² United Nations, Economic and Social Council (1973) *Official Records, Fifty-fourth Session, Resolutions, Supplement No. 1*, Document E/5367, pp. 19–20 (Resolution 1777 (LIV)).

³ United Nations, Economic and Social Council (1973) *Official Records, Fifty-fourth Session, Resolutions, Supplement No. 1*, Document E/5367, pp. 19–21 (Resolutions 1776 and 1780).

⁴ United Nations (1971) *Conference for the Adoption of a Protocol on Psychotropic Substances*, Vienna (Document E/CONF.58/6).

⁵ United Nations, Economic and Social Council (1973) *Official Records, Fifty-fourth Session, Resolutions, Supplement No. 1*, Document E/5367, p. 19 (Resolution 1773 (LIV)).

⁶ Adherence or ratification by 40 countries is required.